Prostate cancer more commonly affects men Scientists say a drug of aggressive prostate cancer may be the result of the most important advances in the effort to overcome such cancers in 70 years.
Abiraterone might be able to treat 80% of patients who develop prostate cancer and deadly kind that is resistant to chemotherapy, scientists said. The drug works by blocking the hormones, which cause the cancer to spread.
Institute of Cancer Research (ICR) hope this drug will be available in pill form in a simple two-or three-year period.
Advanced clinical testing involving 1.200 patients worldwide currently underway. And, further tests may be done this year. Prostate cancer is the most common cancer in men. About 10,000 men in England per year is estimated diagnosed with the most aggressive forms of prostate cancer and almost always fatal.
Life expectancy following chemotherapy is generally not more than 18 months. This cancer is assumed to be controlled by sex hormones such as testosterone. The current treatment is done by blocking the testicle to produce testosterone. However, experts now find that cancer can be cancer can get food on sex hormones from all sources, including the supply of a hormone produced by the tumor itself.
Abiraterone works by blocking the production of hormones throughout the body. Recent research, published in a scientific publication Journal of Clinical Oncology, performed only on 21 patients suffering from advanced stages of aggressive prostate cancer who were treated with the drug. However, research data obtained from 250 patients worldwide.
Study found tumors shrank significantly, and decreased levels of protein produced by the cancer, namely prostate specific antigen in most patients. Many patients reported a significant increase in their quality of life. Some no longer need to take morphine to relieve pain caused by the spread of the disease to the bone.
0 comments:
Post a Comment